Advertisement

Topics

ArQule, Inc. Company Profile

00:44 EST 23rd November 2017 | BioPortfolio

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. The Company is also conducting Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. The Company’s pre-clinical pipeline includes a compound designed to inhibit the B-RAF kinase. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase. The most advanced AKIP™ program is focused on the discovery of inhibitors of fibroblast growth factor receptor (FGFR).


News Articles [24 Associated News Articles listed on BioPortfolio]

ArQule: First Patient Dosed In ARQ 531 Phase 1 Trial For B-cell Malignancies

WASHINGTON (dpa-AFX) - Biopharmaceutical company ArQule, Inc. (ARQL) announced Tuesday that the first patient has been dosed in a phase 1a/b trial with its BTK inhibitor, ARQ 531, in patients with...

ArQule nets $9.3mm through preferred stock sale

In its second private placement in two months, cancer and rare disease drug developer ArQule Inc. netted $9.3mm through the sale of 8,370 Series A convertible preferred shares at $1,135; each preferre...

ArQule Announces Dosing In Registrational Trial Of FGFR Inhibitor Derazantinib

ArQule, Inc. (ARQL) on Tuesday announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib or ARQ 087 in FGFR2 fusion driven second-line intrahepatic Chola...

FDA gives rare pediatric disease designation to ArQule's Proteus syndrome drug

ArQule's orphan drug-tagged miransertib received rare pediatric disease designation from the FDA.  -More- 

Private placement nets $15.5mm for ArQule

ArQule Inc. (cancer and rare disease drug development) netted $15.5mm through a private placement of 13.9mm common shares at $1.14 (a 4% premium) and four-year warrants to purchase 3.1mm shares at $1....

ArQule Announces First Patient Dosed In Phase I Trial Of BTK Inhibitor, ARQ 531, For B-Cell Malignancies

Trial is enrolling patients refractory to standard of care, including ibrutinib BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient ...

FDA Grants Rare Pediatric Disease Designation to ArQule's Miransertib (ARQ 092) for the Treatment of Proteus Syndrome

BURLINGTON, Mass.--(BUSINESS WIRE) November 1, 2017 -- ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to mi...

BRIEF—ArQule awarded rare pediatric disease designation for miransertib

East Coast rare disease and oncology specialist ArQule has been awarded rare pediatric disease designation…

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

ArQule, Inc.

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum produ...

ArQule, Inc. and Daiichi Sankyo Company, Limited

On December 19, 2008, ArQule and Daiichi Sankyo, Co., Ltd. signed a license, co-development and co-commercialization agreement to co-develop tivantinib in the U.S., Europe, South ...

ArQule Incorporated

ArQule has created a new technology platform for the discovery and production of novel chemical compounds with commercial potential. The Company has developed proprietary technologies for the identifi...

More Information about "ArQule, Inc." on BioPortfolio

We have published hundreds of ArQule, Inc. news stories on BioPortfolio along with dozens of ArQule, Inc. Clinical Trials and PubMed Articles about ArQule, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ArQule, Inc. Companies in our database. You can also find out about relevant ArQule, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Corporate Database Quicklinks



Searches Linking to this Company Record